Food and Drug Administration (FDA) has approved four GLP-1 drugs for weight loss in people with overweight or obesity: liraglutide (Saxenda) orforglipron (Foundayo) semaglutide (Wegovy) tirzepatide (Zepound) Liraglutide, semaglutide, and tirzepatide are injectable medications that come in prefilled pens
In addition to the interplay with GLP-1 activity, these bitter and aromatic herbs can help to mitigate many of the undesirable side effects experienced by many patients using GLP-1 therapies, including constipation and nausea
Start by eating smaller, more frequent meals, slowly increasing your fiber intake, and drinking plenty of water throughout the day
It tells fat cells to release stored energy
Individuals with metabolic conditions such as type 2 diabetes and obesity are at an increased risk for developing MASH
Zero preparation variables